Anatomical and Visual Outcomes Following a Single Injection of Intravitreal Faricimab in Patients With Neovascular Age-related Macular Degeneration and Persisting Fluid Despite Frequent Aflibercept Treatments
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- Proportion of patients responding to the treatment switch
研究概览
简要总结
The goal of this retrospective single-center chat review is to establish the efficacy and safety of a single dose of intravitreal faricimab (Vabysmo®) injection in patients with neovascular age-related macular degeneration (AMD), who were previously treated with aflibercept (Eylea®) and had persisting intraretinal or subretinal fluid despite frequent treatments.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Patients
Patients who received intravitreal faricimab injections between May and September, in 2023. and conform the inclusion/exclusion criteria.
干预措施: Faricimab (Drug)
结局指标
主要结局
Proportion of patients responding to the treatment switch
时间窗: 4 weeks
Defined as reduction or disappearance of the intra- or subretinal fluid at 4 weeks following a single injection of faricimab
次要结局
- Durability of a single injection in cases of favorable treatment response without residual fluid(Up to 16 weeks)
- Differences in patient characteristics between individuals responding and not responding to faricimab(4 weeks)
- Changes in visual acuity after the treatment switch(4 weeks)
- Changes in central retinal thickness after the treatment switch(4 weeks)
- Changes in pigment epithelium detachment (PED) height after the treatment switch(4 weeks)
研究者
Miklos Schneider MD, PhD
Staff Specialist
Rigshospitalet, Denmark